Journal article
Multivariate analysis of prognostic parameters using interstitial thermoradiotherapy (IHT-IRT): Tumor and treatment variables predict outcome
International journal of radiation oncology, biology, physics, v 29(5), pp 1049-1063
1994
PMID: 8083074
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Purpose
: From January 1986 to October 1991, 90 patients with localized tumors were treated in a Phase I/II trial using low-dose
192Ir brachytherapy (IRT) plus interstitial 915 MHz microwave (MW) hyperthermia (IHT) and external beam radiotherapy (ERT). Tumors were classified as locally advanced primary (class 1: 27), recurrent (class 2: 40), metastatic (class 3: 10) and persistent (class 4: 13) lesions. The treatment sites included tumors of the head and neck (62), pelvis (26), and others (2). The mean cuboidal tumor volume was 63 cm
3 (range: 8–288 cm
3). Most recurrent and metastatic lesions (48) had received prior treatment including ERT.
METHODS AND MATERIALS
: The treatment protocol prescribed two heating sessions (each 60 min) at 41–44°C before and after IRT. One hundred sixty-one IHT sessions were evaluated. Invasive thermal data were recorded at an average of 18 sites throughout the implant volume. Several thermal variables were analyzed (e.g., averaged parameters:
Tmax
av,
Tmean,
Tmin
av; index parameters:
T
10,
T
50,
T
90). The study was evaluated minimum follow up (FU) of one year. Median follow-up was 19 months.
Results
: At 3 months FU, a complete response (CR) was observed in 59 of 90 (66%) patients. At 12 months FU, local control (LC) was achieved in 54 of 84 (64%) evaluable patients. Ten patients developed a local and 14 a regional recurrence (REC) after achieving a CR and/or LC. At last FU, a total of 31 (34%) patients were still alive and 28 (31%) patients had relapse-free survival. For all 90 patients, the median overall survival was 20 months and the median relapse-free survival was 17 months. Overall and relapse-free survival was significantly longer for primary and persistent lesions as compared to recurrent and metastatic lesions (
p = 0.002;
p < 0.001). Totally 22 (24%) patients experienced acute or subacute side-effects (Grade 1: 12 patients; Grade 2: eight patients; Grade 3: two patients).
Conclusion
: Univariate logistic regression analysis revealed significant dependencies of CR, LC and REC upon tumor parameters as well as radiation and thermal parameters. The overall and relapse free survival was associated with tumor and radiation parameters. The multivariate analysis revealed two independent predictors of CR: tumor volume and minimum tumor temperature variables. We conclude, that IHT-IRT is a safe and effective treatment. The results provide important implications for planning HT-RT studies and for defining quality assurance (QA) criteria and thermal performance standards in HT studies.
Metrics
Details
- Title
- Multivariate analysis of prognostic parameters using interstitial thermoradiotherapy (IHT-IRT): Tumor and treatment variables predict outcome
- Creators
- M. Heinrich Seegenschmiedt - Strahlentherapeutische Klinik, Universität Erlangen-Nürnberg, Universitätsstraße 27, GermanyPeter Martus - Institut für Angewandte StatistikRainer Fietkau - University of Erlangen-NurembergHeinrich Iro - University of Erlangen-NurembergLuther W. Brady - Hahnemann University HospitalRolf Sauer - University of Erlangen-Nuremberg
- Publication Details
- International journal of radiation oncology, biology, physics, v 29(5), pp 1049-1063
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:A1994PE33800016
- Scopus ID
- 2-s2.0-0028111779
- Other Identifier
- 991019184043504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging